|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 9.76 EUR | -1.36% |
|
+5.68% | -54.14% |
| May. 03 | EVOTEC : RBC reiterates its Buy rating | ZD |
| Apr. 30 | Bayer: strategic collaboration with Evotec | CF |
Evotec SE reported earnings results for the full year ended December 31, 2023. For the full year, the company reported sales was EUR 781.43 million compared to EUR 751.45 million a year ago. Net loss was EUR 83.91 million compared to EUR 175.66 million a year ago.
Basic loss per share from continuing operations was EUR 0.47 compared to EUR 0.99 a year ago. Diluted loss per share from continuing operations was EUR 0.47 compared to EUR 0.99 a year ago.
| 1st Jan change | Capi. | |
|---|---|---|
| -54.14% | 1.86B | |
| +25.69% | 47.86B | |
| +46.90% | 41.42B | |
| -3.46% | 40.66B | |
| -6.20% | 28.92B | |
| +9.17% | 25.55B | |
| -20.42% | 19.27B | |
| +0.17% | 12.15B | |
| +28.07% | 12.14B | |
| -1.24% | 11.99B |
EVOTEC SE 
